CA3211110A1 - 4-aminoquinazoline compound - Google Patents

4-aminoquinazoline compound Download PDF

Info

Publication number
CA3211110A1
CA3211110A1 CA3211110A CA3211110A CA3211110A1 CA 3211110 A1 CA3211110 A1 CA 3211110A1 CA 3211110 A CA3211110 A CA 3211110A CA 3211110 A CA3211110 A CA 3211110A CA 3211110 A1 CA3211110 A1 CA 3211110A1
Authority
CA
Canada
Prior art keywords
compound
methyl
diazabicyclo
fluoro
methy1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3211110A
Other languages
English (en)
French (fr)
Inventor
Kenichi Kawaguchi
Kazuyuki Kuramoto
Tomoyoshi IMAIZUMI
Takahiro Morikawa
Mitsuaki Okumura
Sunao Imada
Eiji Kawaminami
Ryo Sato
Yohei Seki
Hisao Hamaguchi
Hiroki Ishioka
Hiroki Fukudome
Ikumi Kuriwaki
Takeyuki Nagashima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of CA3211110A1 publication Critical patent/CA3211110A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3211110A 2021-02-15 2022-02-14 4-aminoquinazoline compound Pending CA3211110A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021021684 2021-02-15
JP2021-021684 2021-02-15
PCT/JP2022/005583 WO2022173033A1 (ja) 2021-02-15 2022-02-14 ４－アミノキナゾリン化合物

Publications (1)

Publication Number Publication Date
CA3211110A1 true CA3211110A1 (en) 2022-08-18

Family

ID=82838845

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3211110A Pending CA3211110A1 (en) 2021-02-15 2022-02-14 4-aminoquinazoline compound

Country Status (12)

Country Link
US (1) US20240150366A1 (https=)
EP (1) EP4293025B1 (https=)
JP (1) JP7725511B2 (https=)
KR (1) KR20230145360A (https=)
CN (1) CN116867788A (https=)
AU (1) AU2022219651A1 (https=)
CA (1) CA3211110A1 (https=)
ES (1) ES3054794T3 (https=)
MX (1) MX2023009520A (https=)
PL (1) PL4293025T3 (https=)
SA (1) SA523450286B1 (https=)
WO (1) WO2022173033A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024008849A (es) 2022-01-21 2024-07-25 Usynova Pharmaceuticals Ltd Compuestos de benzopirimidina y uso de estos.
AU2023231912A1 (en) * 2022-03-11 2024-08-15 Astellas Pharma Inc. Heterocyclic compound for inducing degradation of g12d mutant kras protein
JP7733274B1 (ja) * 2022-08-12 2025-09-02 アステラス製薬株式会社 Ｇ１２ｄ変異ｋｒａｓ阻害活性を有する二官能性化合物を含む抗がん剤の組合せ
AR130192A1 (es) * 2022-08-12 2024-11-13 Astellas Pharma Inc Combinaciones antineoplásicas que comprenden quimioterapia
WO2024188281A1 (zh) * 2023-03-13 2024-09-19 南京明德新药研发有限公司 含喹唑啉结构的化合物及其应用
AU2024337913A1 (en) 2023-09-08 2026-03-26 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
WO2025052649A1 (ja) * 2023-09-08 2025-03-13 アステラス製薬株式会社 単一の軸不斉化合物の選択的製造法
US20250114339A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor
AU2024357850A1 (en) 2023-10-09 2026-04-23 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
WO2016049565A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Compositions and methods for inhibition of ras
WO2017172979A1 (en) * 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
JOP20190186A1 (ar) * 2017-02-02 2019-08-01 Astellas Pharma Inc مركب كينازولين
US20220363681A1 (en) * 2019-08-16 2022-11-17 Genfleet Therapeutics (Shanghai) Inc. Oxo six-membered cyclopyrimidine compound, preparation method and medical use thereof
WO2021041671A1 (en) 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation

Also Published As

Publication number Publication date
EP4293025A4 (en) 2025-02-26
SA523450286B1 (ar) 2024-06-12
AU2022219651A1 (en) 2023-09-07
US20240150366A1 (en) 2024-05-09
MX2023009520A (es) 2023-08-24
EP4293025B1 (en) 2025-10-29
JP7725511B2 (ja) 2025-08-19
EP4293025C0 (en) 2025-10-29
JPWO2022173033A1 (https=) 2022-08-18
PL4293025T3 (pl) 2026-02-16
WO2022173033A1 (ja) 2022-08-18
EP4293025A1 (en) 2023-12-20
CN116867788A (zh) 2023-10-10
ES3054794T3 (en) 2026-02-06
KR20230145360A (ko) 2023-10-17

Similar Documents

Publication Publication Date Title
CA3211110A1 (en) 4-aminoquinazoline compound
CN110267957B (zh) 喹唑啉化合物
AU2022221145A1 (en) Quinazoline compound for inducing degradation of G12D mutant KRAS protein
WO2022037568A1 (en) Bicyclic compounds, compositions and use thereof
AU2015280138B2 (en) Phosphatidylinositol 3-kinase inhibitors
CN120092011A (zh) Kras g12d抑制剂
CN119768398A (zh) 抑制和/或诱导kras蛋白降解的杂环化合物
AU2016280137B2 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
SG188302A1 (en) Fused heteroaryls and their uses
CN113966336B (zh) 三环类化合物及其用途
CA3078942A1 (en) Pyrrolotriazine compounds and methods of inhibiting tam kinases
CA3130049C (en) 7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative
WO2025159142A1 (ja) Ｋｒａｓタンパクの分解を誘導するための複素環化合物
WO2023218195A1 (en) Gcn2 inhibitorr
CN104822658B (zh) 作为多种激酶抑制剂的稠合三环酰胺类化合物
WO2025103502A1 (en) Compounds and methods of treating cancers
AU2024353668A1 (en) Cbl-b inhibitors and methods of uses thereof
TWI894448B (zh) Ctla-4小分子降解劑及其應用
CN119053596A (zh) 作为激酶抑制剂的杂环化合物、其组合物及使用方法
HK40085586A (en) Pyridazinyl thiazolecarboxamide compound
HK40108597A (en) Heteroaryl derivative compound and use thereof
EA050883B1 (ru) 8-окса-3-азабицикло[3.2.1]октановые соединения или их соли, способ их получения и применение
WO2026086768A1 (zh) 杂环抑制剂及其制备方法和用途
JP2024533046A (ja) ＡｈＲシグナル伝達の調節に有用な化合物

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241223

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241223

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241223

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260108

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260108

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260109